Ultimovacs has announced that the first patient has been enrolled in FOCUS. FOCUS is an investigator-led Phase II randomized clinical trial in head-and-neck cancer of the company’s telomerase cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab. “Initiation of reAlready a subscriber Login You have read all your free…